- Home
- Supplements
- Kudzu Root
- Cholesterol Management
Kudzu Root for Cholesterol Management
Kudzu isoflavones show lipid effects in animal models, but no human trials support kudzu for cholesterol management.
Overview
Verdict
Preclinical interest only — human lipid data absent.
How It Works
Dosing & Protocol
Typical dose
- Recommended dose
- No validated dose for lipids
- Expected timeframe
- Unknown
Protocol
- form
- Not applicable
- duration
- Not applicable
- co factor
- Evidence is insufficient. Kudzu root contains isoflavones including puerarin, daidzein and genistein, and rodent studies report reductions in total and LDL cholesterol along with anti-inflammatory and antioxidant effects, with plausible mechanisms via oestrogen receptor signalling and lipid metabolism. Puerarin has also been studied by injection in Chinese cardiovascular practice. But there are no adequate randomised controlled trials of oral kudzu root for cholesterol in humans - the human research on kudzu concerns reducing alcohol intake, where small trials do show an effect, and menopausal symptoms. Extrapolating a rodent lipid finding to a clinical recommendation is not justified.
- titration
- Not applicable
- starting dose
- Not applicable as an established treatment
Evidence
What the studies say
No studies are yet linked to both Kudzu Root and Cholesterol Management.
Safety
Caveats
Raised cholesterol is a major modifiable cardiovascular risk factor with treatments of proven mortality benefit - statins and ezetimibe - and it should not be managed with an unproven botanical. Do not stop or reduce prescribed lipid-lowering medication. Safety: kudzu isoflavones are phytoestrogens with oestrogen receptor activity, so avoid in hormone-sensitive cancers including breast, ovarian and uterine, and in endometriosis or uterine fibroids, without oncology advice. Kudzu may interact with tamoxifen and hormonal therapies, and with methotrexate. It may lower blood glucose - monitor if taking insulin or sulfonylureas - and may add to the effects of antihypertensives. Case reports of liver injury exist with kudzu-containing preparations, so avoid in liver disease and stop if jaundice, dark urine or right upper quadrant pain develops. There is no established upper intake level and no long-term safety data. Avoid in pregnancy and breastfeeding, where the phytoestrogen content makes safety particularly uncertain, and in children.
Less likely to help if
Medical Disclaimer
The information provided on this website is for educational and informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or before starting any supplement regimen.
Individual results may vary. The statements on this website have not been evaluated by the Food and Drug Administration. Products and information are not intended to diagnose, treat, cure, or prevent any disease.